Orion OYJ (OTCMKTS:ORINY) Releases Quarterly Earnings Results

Orion OYJ (OTCMKTS:ORINY - Get Free Report) posted its quarterly earnings data on Friday. The company reported $0.33 earnings per share for the quarter, Zacks reports. The business had revenue of $472.57 million during the quarter. Orion OYJ had a return on equity of 38.40% and a net margin of 22.61%.

Orion OYJ Price Performance

OTCMKTS ORINY remained flat at $38.88 on Monday. The company had a trading volume of 83 shares, compared to its average volume of 94. The firm has a market cap of $10.97 billion, a price-to-earnings ratio of 26.45 and a beta of 0.10. Orion OYJ has a 1-year low of $21.10 and a 1-year high of $39.39. The business has a fifty day moving average price of $35.45 and a 200 day moving average price of $30.53. The company has a current ratio of 3.79, a quick ratio of 2.27 and a debt-to-equity ratio of 0.27.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.